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ABSTRACT
Extended-spectrum b-lactamases (ESBLs) are usually plasmid-mediated enzymes that confer resistance
to a broad range of b-lactams. Initially, resistance to third-generation cephalosporins in Gram-negative
rods was mainly due to the dissemination of TEM- and SHV-type ESBLs, which are point mutants of the
classic TEM and SHV enzymes with extended substrate speciﬁcity. During the last ten years, CTX-M-
type ESBLs have become increasingly predominant, but less frequent class A b-lactamases have also
been described, including SFO, BES, BEL, TLA, GES, PER and VEB types. While several of these latter
are rarely identiﬁed, or are very localised, others are becoming locally prevalent, or are increasingly
isolated worldwide. In addition, mutations can extend the spectrum of some OXA-type b-lactamases to
include expanded-spectrum cephalosporins, and several of these enzymes are considered to be ESBLs.
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INTRODUCTION
b-Lactamases are most commonly classiﬁed
according to two general schemes: the Ambler
molecular classiﬁcation and the Bush–Jacoby–
Medeiros functional system [1,2]. A commonly
used working deﬁnition of extended-spectrum
b-lactamases (ESBLs) is: b-lactamases capable of
conferring bacterial resistance to the penicillins,
ﬁrst-, second-, and third-generation cephalospor-
ins and aztreonam (but not to cephamycins or
carbapenems) with hydrolysis rates of at least
10% of that of benzylpenicillin and inhibited by
b-lactamase inhibitors such as clavulanate [3]. The
extension of the spectrum of some OXA-type
b-lactamases towards the expanded-spectrum
cephalosporins has also been observed, and
several of these enzymes are considered to be
ESBLs, even though they are poorly inhibited by
clavulanate [3–5].
Although ESBLs have been reported most fre-
quently in Enterobacteriaceae, they have been
found in other bacterial species, such as Pseudomo-
nas aeruginosa andAcinetobacter baumannii [3,4]. For
the purpose of this review, the term ESBL will be
taken to mean those b-lactamases of Bush–Jacoby–
Medeiros group 2be (molecular class A enzymes)
and those of group 2d (OXA; molecular class D
enzymes), which share most of the properties
of group 2be enzymes [3,5]. Initially, the 2be
designation indicated that these enzymes are
derived from group 2b b-lactamases (such as
TEM-1 and SHV-1), with the letter ‘e’ denoting
extended-spectrum activity. Subsequently, CTX-M
enzymes have also been placed into the 2be
group, even though the progenitors of these en-
zymes are naturally capable of hydrolysing third-
generation cephalosporins and aztreonam [3].
While the majority of clinically isolated ESBLs
are TEM, SHV or CTX-M types [3,6], several
ESBLs that are not closely related to any of the
three established families have been reported.
Examples include the SFO, BES, BEL, TLA, GES,
PER and VEB types (Tables 1 and 2, Fig. 1). These
are not simple point-mutant derivatives of any
known b-lactamases and, except for SFO-1, their
progenitor genes remain unknown. These ESBLs
are remarkable for their geographical diversity.
This review describes the properties and the
distribution of these infrequent class A and
class D ESBLs, whether chromosomal- or plas-
mid-encoded.
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CHROMOSOMAL-ENCODED ESBLs
Several Gram-negative species have inherent
ESBL genes carried by their chromosome. In these
bacteria, the presence of a single b-lactamase gene
copy, with a weak promoter, may yield only low-
level expression of the resistance phenotype [7].
Those Enterobacteriaceae that naturally pro-
duce an ESBL are resistant to amino-penicillins,
variably resistant to carboxy-penicillins, with this
resistance being reversed by inhibitors of class A
enzymes such as clavulanate, variably resistant to
ﬁrst- and second-generation cephalosporins, and
susceptible to third-generation cephalosporins.
Synergy may be observed between ﬁrst-, second-
and sometimes third- or even fourth-generation
cephalosporins and clavulanate. This phenotype
is speciﬁc for a given species, such as Proteus
vulgaris (CumA), Proteus penneri (HUGA), Erwinia
persicina (ERP-1), Citrobacter sedlakii (SED-1), Kluy-
vera spp. (KLUA, KLUC, KLUG), Serratia fonticola
(FONA), Rahnella aquatilis (RAHN-1) [7–9], or
Klebsiella oxytoca (K1 or Koxy) [2,3].
Non-fermentative Gram-negative rods (e.g.,
Stenotrophomonas maltophilia (L2 enzyme), Chry-
seobacterium meningosepticum (CME-1 ⁄ 2), Chryseo-
bacterium gleum (CGA-1) and Burkholderia
pseudomallei (PENA)) and strictly anaerobic bac-
teria (Desulfovibrio desulfuricans (DES-1), Prevotella
intermedia (CFXA2) and Bacteroides fragilis
(CEPA)) have also been shown to possess ESBL
genes [10,11].
These chromosomally encoded enzymesmay be
at the origin of plasmid-encoded enzymes.
b-Lactamases of theCTX-Mgroups are structurally
related to the naturally produced b-lactamases of
Kluyvera ascorbata (CTX-M-2) Kluyvera georgiana
(CTX-M-8), Kluyvera cryocrescens (CTX-M-1), and
Kluyvera spp. isolated in Guyana (CTX-M-9) [6].
Similarly, the plasmid-encoded SFO-1 enzyme is
highly related to the chromosomally encoded
FONA-1 enzyme from S. fonticola [9,12]. A den-
drogram of the phylogeny of some chromosomal-
and plasmid-encoded ESBLs is shown in Fig. 1.
PLASMID-ENCODED ESBLs
Besides the CTX-M-type enzymes, several other
plasmid-mediated ESBLs are not simple point-
mutant derivatives of classic b-lactamases. While
some of these enzymes have so far been isolated
only once or twice, others are increasingly being
isolated worldwide (Tables 1 and 2).
Rare ESBLs
SFO-1.
SFO-1 was found in a single clinical Enterobacter
cloacae isolate from Japan in 1988 [12]. SFO-1
hydrolyses cefotaxime very efﬁciently, ceftazi-
dime poorly, and spares cephamycins and carba-
penems. Its activity is inhibited by clavulanate
and imipenem. An unusual feature of SFO-1,
which is highly related to a class A b-lactamase
Table 1. Plasmid-encoded
extended-spectrum
b-lactamases
b-Lactamase
name Yeara
No. of
variants Origin of the name
‘Old ESBL’
SHV type 1983 >100 Sulphhydryl variable
TEM type 1985 >160 Patient’s name: Temoneira
‘New ESBL’
CTX-M type 1989 >65 Cefotaximase—Munich
‘Minor ESBL’
SFO-1 1988 1 Serratia fonticola
TLA-1 1991 1 Tlahuicas (Indian tribe)
PER 1991 3 Pseudomonas extended resistance
VEB 1996 5 Vietnam extended-spectrum
b-lactamase (ESBLs)
BES-1 1996 1 Brazilian ESBLs
GES 1998 9 Guyana ESBLs
BEL-1 2005 1 Belgium ESBLs
TLA-2 2005 1 51% amino-acid identity with TLA-1
OXA ESBLs
OXA 1991 At least 9 Hydrolysis of oxacillin > penicillin
aYear ﬁrst recorded.
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from S. fonticola, is that it was encoded on a self-
transferable plasmid and that the b-lactamase
production was induced to a high level by
imipenem [9,12]. The encoding plasmid also
carries the ampR regulatory gene necessary for
the induction of the b-lactamase in a manner
similar to class C b-lactamases. However, unlike
class C b-lactamases, SFO-1 cannot hydrolyse
cephamycins and is well-inhibited by clavulanate
[12].
BES-1.
BES-1was isolated once from a Serratia marcescens
strain from a hospital in Rio de Janeiro (Brazil)
in 1996 [13]. It confers a high level of resistance
to aztreonam and a higher level of resistance to
cefotaxime than to ceftazidime. Its activity
against cefotaxime resembles that of CTX-M
types; however, BES-1 is more active against
ceftazidime and has a 1000-fold higher afﬁnity
for aztreonam.
The blaBES-1 gene is plasmid-encoded and its
product belongs to functional group 2be, with
48% amino-acid identity with the CTX-M group 1
b-lactamases. BES-1 is well-inhibited by clavula-
nate, whereas tazobactam is a poor inhibitor [13].
BEL-1.
BEL-1 was identiﬁed in a P. aeruginosa strain
isolated in Belgium in 2004, which displayed on
a disk diffusion antibiogram an image of synergy
between clavulanate and ceftazidime containing
disks, thus indicating the presence of an ESHL [14].
BEL-1 is weakly related to other Ambler class A
ESBLs (50% amino-acid identity with GES-1 ESBL,
40%with CTX-M group 8, 36%with BES-1). BEL-
1 signiﬁcantly hydrolyses most expanded-spec-
trum cephalosporins and aztreonam, and its
activity is well-inhibited by clavulanate, cefoxitin,
moxalactam, and imipenem, whereas tazobactam
is a poor inhibitor, as with BES-1. The blaBEL-1 gene
is chromosomally located and is embedded in a
Fig. 1. Phylogeny of some chromo-
somal- and plasmid-encoded
extended-spectrum b-lactamases
(ESBLs). Plasmid-encoded minor
class A ESBLs are boxed and OXA
ESBLs are indicated. The dendro-
gram was constructed using CLUS-
TALW aligned protein sequences.
44 Clinical Microbiology and Infection, Volume 14, Supplement 1, January 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 42–52
class 1 integron containing three other gene cas-
settes [14]. Recent work suggests that the blaBEL-1
gene might be disseminating in Belgium in clinical
and community P. aeruginosa isolates [15].
TLA-1.
TLA-1 was identiﬁed in an Escherichia coli isolate
from a patient in Mexico in 1993 [16]. It hydro-
lyses expanded-spectrum cephalosporins, includ-
ing cefotaxime, ceftazidime, aztreonam and
cefepime, but not imipenem and cefoxitin. It is
strongly inhibited by tazobactam and, to a lesser
extent, by clavulanate and sulbactam. The blaTLA-1
gene is localised on a self-transferable plasmid. Its
amino-acid sequence shares 50% identity with
CME-1, the chromosomal class A b-lactamase
from C. meningosepticum, and c. 40% homology
with the plasmid-encoded VEB and PER en-
zymes. Nosocomial bacteraemia and urinary tract
infections caused by Klebsiella pneumoniae with
plasmids carrying both SHV-5 and TLA-1 genes
have been recently described in Mexico [17]. TLA-
1 remains unreported outside of Mexico.
TLA-2.
TLA-2 is encoded by a 47-kb plasmid that was
isolated from an unidentiﬁed bacterial strain
obtained from the activated sludge compartment
of a wastewater treatment plant in Germany in
2002 [18]. TLA-2 is an Ambler class A b-lactamase
that shares 52% amino-acid identity with CGA-1
from C. gleum and only 51% with TLA-1 from
E. coli. TLA-2 has good catalytic efﬁciency against
most cephalosporins, but not against penicillins,
and it lacks sensitivity to b-lactam inhibitors.
Although there is no evidence yet for diffusion of
TLA-2 into clinical settings, the fact that this
enzyme can degrade expanded-spectrum cepha-
losporins and is encoded by a plasmid that can be
mobilised may indicate future clinical relevance.
Increasingly isolated ESBLs
PER-1.
PER-1 was initially detected in 1993 in a
P. aeruginosa isolate from a Turkish patient hospi-
talised in France [19,20]. This enzyme is weakly
related to other ESBLs and confers resistance to
penicillins, cefotaxime, ceftazidime, and aztreo-
nam but spares carbapenems and cephamycins.
Its activity is well-inhibited by clavulanate,
sulbactam and tazobactam [19,20]. Although
PER-1 is typical among class A enzymes in its
catalytic machinery, its three-dimensional struc-
ture reveals that it forms a subgroup in the
class A superfamily, with a new fold in the
W-loop a region, considered to be a canonical
motif in class A enzymes [20,21]. Several enzymes
with signiﬁcant sequence identity (40%) were
subsequently identiﬁed as belonging to the ‘PER-
like’ family: PER-2, VEB-1, TLA-1 and chromoso-
mal CME-1 from C. meningosepticum [21].
The blaPER-1 gene is widespread in Acinetobacter
spp. and P. aeruginosa, but can also be isolated
Table 2. MICs (mg ⁄L) for clinical strains, Escherichia coli strains harbouring recombinant plasmids (rec) or E. coli
transformant (Tc) strains
b-Lactamase Species TIC TCC PIP TAZ CTX CAZ CAZ-Ac FEP ATM IPM
SFO-1a Enterobacter cloacae 128 4 16 1
Escherichia coli (Tc) 8 2 16 0.25
BES-1b Serratia marcescens >512 512 512 256 64 4 1 4 512 0.5
E. coli (rec) >512 32 512 256 64 16 0.25 8 512 0.25
TLA-1c E. coli >256 >256 4 64 >256 1
PER-1d Pseudomonas aeruginosa >512 256 8 8 256 256 32 256 1
Salmonella Typhimurium >512 128 256 64 256 512 128 128 0.12
E. coli (Tc) >512 1 16 2 128 512 8 512 0.06
VEB-1e P. aeruginosa >512 8 256 8 >512 >512 16 256 512 0.5
E. coli (Tc) 256 4 16 2 2 256 1 1 32 0.12
BEL-1f P. aeruginosa >512 128 16 8 32 32 4 4 32 1
E. coli (rec) >512 64 128 32 1 16 2 0.25 16 0.06
GES-1g Klebsiella pneumoniae >512 64 512 64 0.5 4 0.5 0.25 0.12 0.12
E. coli (Tc) 256 8 16 2 0.5 8 1 0.25 0.25 0.06
a[12]; b[13]; c[16]; d[19]; e[41]; f[14]; c[52].
TIC, ticarcillin; TCC, ticarcillin ⁄ clavulanate; PIP, Piperacillin; TAZ, Piperacillin/Tazocillin; CTX, Cefotaxim; CAZ,
Ceftazidime; CAZ-Ac, Ceftazidime/clavulanatc; FEP, Cefepime; ATM, Aztreonam; IPM, imipenem.
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from Salmonella enterica serovar Typhimurium
and Providencia rettgeri in Turkey [22,23]. A recent
survey in Turkish intensive care units revealed
that, among ceftazidime-resistant nosocomial iso-
lates of Acinetobacter spp. and P. aeruginosa, 32%
and 55%, respectively, had the PER-1 enzyme
[22].
Although organisms expressing PER-1 have
been found predominantly in Turkey, outbreaks
of P. aeruginosa with the enzyme have occurred in
Italy, with no apparent contacts with Turkish
patients [24]. Worryingly, a P. aeruginosa strain
producing both PER-1 and the carbapenemase
VIM-2 has been detected in Italy [25]. This
combination renders the organism resistant to
virtually all b-lactam antibiotics. PER-1 has also
been found in Proteus mirabilis and Alcaligenes
faecalis in Italy [26,27]. A recent survey of ESBL-
producing Enterobactericeae conducted in a
French university hospital in 2002 and in Spain
in 2005 revealed PER-1 in enterobacterial isolates,
e.g., Providencia stuartii [28] and P. mirabilis [29].
Isolates of P. aeruginosa and A. baumannii produ-
cing PER-1 have been detected on several occa-
sions in France, Belgium and recently in Japan
[30–32], and a high prevalence of PER-1 in
Acinetobacter spp. from Korea was noted [33].
PER-3, a point-mutant derivative of PER-1, was
identiﬁed in Aeromonas caviae in France [34].
A related enzyme, PER-2,which has 86% amino-
acid homology with PER-1, was found among
S. enterica serovar Typhimurium strains in
Argentina in 1996 [35] and subsequently in other
Gram-negative bacteria, including S. enterica ser-
ovar Senftenberg, K. pneumoniae, Enterobacter aero-
genes, E. cloacae, Vibrio cholerae and, recently,
A. baumannii. It has been reported in Argentina,
Uruguay, and Bolivia [36–40]. Whereas PER-1 is
reported mostly in Turkey and Korea, PER-2 has
only been reported in South America thus far.
VEB-1.
The blaVEB-1 gene, ﬁrst reported in 1996 in relation
to an E. coli isolate from a Vietnamese patient, is
plasmid- and integron-located [41,42]. VEB-1 has
highest amino-acid identity with PER-1 and PER-
2 (38%) [20], and confers high-level resistance to
ceftazidime, cefotaxime and aztreonam. VEB-1 is
equally well-inhibited by clavulanate, sulbactam
and tazobactam, and also by moxalactam, imipe-
nem and cefoxitin, as best evidenced in enter-
obacterial isolates on disk diffusion antibiogram
by an unusual image of synergy between a
cefoxitin- and a cefuroxime-containing disk. The
activity against expanded-spectrum cephalospor-
ins is very high in general, except for ceftazidime
and aztreonam, whereas the hydrolytic activities
against penicillins are much lower [41].
After its initial discovery, the blaVEB-1 gene was
detected in two P. aeruginosa isolates from Thai-
land, where it was chromosomal- and integron-
located [43]. Several epidemiological surveys in
Thailand and Vietnam have emphasised the
widespread distribution of VEB-1. In these coun-
tries, up to 40% and 80% of ceftazidime-resistant
enterobacteriacae and P. aeruginosa isolates, re-
spectively, were positive for blaVEB-1 [43–45]. Four
single point-mutant derivatives of VEB-1 (VEB-2
to -5) have been described (http://www.lahey.
org/Studies/other.asp#table1).
In addition, single VEB-producing isolates have
been detected in P. aeruginosa isolates from
Kuwait, China, India and Bangladesh, in A. bau-
mannii isolates from France, Belgium and Argen-
tina, in P. stuartii isolates from Algeria, in
E. cloacae and Achromobacter xylosoxidans isolates
from France, and in E. coli isolates from Canada
[28,29,40,46,47]. Outbreaks involving isolates with
VEB-1 enzymes have been described, including a
nationwide outbreak of VEB-1 A. baumannii in
France and Belgium [29,48], P. mirabilis in Korea
[49] and VEB-3 E. cloacae in China [50].
In most instances, VEB-1 is integron-borne and
can be associated with several other resistance
genes. In the prototype E. coli producer MG-1, the
blaVEB-1 gene was carried on an integron, In53,
that contained eight additional gene cassettes,
including those coding for the OXA-10 b-lacta-
mase, several aminoglycoside resistance markers,
and the rifampin ADP ribosyltransferase, chlor-
amphenicol resistance marker, and one specifying
resistance to quaternary ammonium compounds
[42].
The blaVEB-1 gene was characterised in a
peculiar genetic environment in P. aeruginosa
isolates from India and Bangladesh and in
P. stuartii from Algeria. Instead of being part of
a typical class 1 integron structure, the blaVEB-1
gene is ﬂanked by identical 135-bp sequences,
termed repeated elements (Res), which are
bracketed by two truncated 3¢-conserved se-
quences of class 1 integrons in direct repeat [46].
These Re structures carry a strong promoter that
drives the expression of the downstream-located
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blaVEB-1a gene. This is a novel ﬁnding, since most
ESBL genes have been reported to be associated
with either transposons or integrons, but always
with a single type of genetic vehicle. The ﬁnding
of a similar structure on different continents
suggests that these Re elements may be wide-
spread and that blaVEB-1 genes may disseminate
via different genetic elements [46].
A frequent association of the plasmid-mediated
quinolone resistance determinant qnrA and the
blaVEB-1 gene has been identiﬁed in enterobacterial
isolates from France, Turkey, Thailand and
Canada [51]. This association may explain, in
part, the frequent co-resistance to quinolones and
expanded-spectrum b-lactams in isolates produ-
cing VEB-1 b-lactamase.
GES.
ESBLs of the GES type (also named IBC) are
reported increasingly in Gram-negative rods,
including P. aeruginosa, E. coli and K. pneumoniae
[52,53]. The current GES nomenclature is avail-
able via the Lahey Clinic website (http://
www.lahey.org/studies/webt.html). GES-1 was
initially characterised in a K. pneumoniae isolate
from France, where it was plasmid- and integron-
encoded [52]. GES-2 was from South Africa, GES-
5, GES-6, GES-7 and GES-8 were from Greece, and
GES-3 and GES-4 were from Japan (Table 3; [54].
GES-5 has also been reported recently from
Korea, China and Brazil [55,56]. Thus, similar
GES variants have now been identiﬁed in widely
separated countries (Table 3 [54]).
GES-1 possesses a hydrolysis proﬁle similar to
that of classic clavulanate-inhibited Ambler class
A ESBLs, including activity against penicillins
and expanded-spectrum cephalosporins, but not
cephamycins and carbapenems, and is inhibited
by clavulanate, tazobactam and imipenem [52].
Unlike most ESBLs, GES-1 does not hydrolyse
aztreonam. GES-2 also hydrolyses carbapenems
and is less susceptible to inhibitors, due to a 2-bp
substitution (Table 3) (Fig. 1), leading to a single
Gly170Asn change inside the W-loop of the
catalytic site [57]. A Gly170Ser change was
identiﬁed in GES-4, GES-5, and GES-6 (Table 3),
resulting in slow carbapenem hydrolysis, weak
inhibitor susceptibility (as for GES-2), but, addi-
tionally, cephamycin hydrolysis, as shown for
GES-4 [58]. GES-9, which differs from GES-1 by a
Gly243Ser change (Table 3), does not hydrolyse
carbapenems but has broadened activity against
monobactams [59].
Worryingly, P. aeruginosa strains producing
GES-1 and the carbapenemase VIM-11 and E. coli
strains producing GES-7 and the carbapenemase
VIM-2, encoded on separate integrons, have been
detected in Greece and in Argentina, respectively,
and are virtually pan-resistant isolates [60,61].
Several outbreaks of Gram-negative bacteria
producing GES variants have been described:
K. pneumoniae in Korea, Portugal and Greece;
S. marcescens in The Netherlands; and P. aerugi-
nosa in South Africa [59, 62–66].
GES-2 is the ﬁrst described example of an ESBL
that extended its spectrum of activity against
carbapenems by a single point mutation. Subse-
quently, four other variants with similar carbape-
nemase activity have been described (GES-4, GES-
5, GES-6 and GES-8). This may represent an
intermediate step between ESBLs and class A
carbapenem-hydrolysing enzymes such as KPC.
In fact, KPC-type enzymes possess the properties
required for being called ESBLs, but are also
capable of signiﬁcant carbapenem hydrolysis [67].
OXA ESBLs
Although the deﬁnition of ESBLs is often re-
stricted to class A enzymes, several oxacillinases
with extended-spectrum activity may be also
included, and are called OXA ESBLs [3–5].
In general, the OXA b-lactamases (group 2d)
are so named because of their oxacillin-hydrolys-
ing abilities, with hydrolysis rates for cloxacillin
and oxacillin being greater than 50% that for
benzylpenicillin [5]. They predominantly occur in
P. aeruginosa but have been detected in many
other Gram-negative bacteria, including Entero-
bacteriaceae [5]. Most OXA-type b-lactamases do
not signiﬁcantly hydrolyse the expanded-spec-
trum cephalosporins, and the evolution of OXA-
type ESBLs from parent enzymes with narrower
spectra has many parallels with the evolution of
SHV- and TEM-type ESBLs. While most OXA-
type ESBLs derive from OXA-10 (OXA-11, OXA-
14, OXA-16 and OXA-17) or OXA-13, which is a
ten-amino-acid derivative of OXA-10, (OXA-19
and OXA-28) or to a lesser extent from OXA-2
(OXA-15 and OXA-32), others are unrelated to
any recognised broad-spectrum OXA enzymes,
e.g., OXA-18 and OXA-45 [3,5,68–70].
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OXA-10 and OXA-13 themselves weakly
hydrolyse cefotaxime, ceftriaxone and aztreonam,
thus providing most organisms with reduced
susceptibility to these antibiotics. Most OXA-
10-derived ESBLs confer greater resistance to
cefotaxime, and signiﬁcant resistance to ceftazi-
dime and aztreonam, except for OXA-17, which
has little effect on the MICs of ceftazidime, but
has substantial activity against cefotaxime [4,5].
OXA ESBLs exhibit appreciable diversity in their
enzymic activities. Although most OXA-type
enzymes are resistant to b-lactamase inhibitors,
OXA-18 and OXA-45 have been reported to be
very well inhibited by clavulanate [69,70].
There are very few epidemiological data on the
geographical spread of OXA-type ESBLs. The
OXA-type ESBLs were originally discovered in
P. aeruginosa isolates from a single hospital in
Ankara, Turkey [68]. These were mostly OXA-10
derivatives, and a recent survey revealed that
they were present in 55% of ceftazidime-resistant
P. aeruginosa isolates from intensive care units in
Istanbul, Turkey [23]. OXA ESBLs have also been
characterised in 2.9% and in 0.4% of ceftazidime-
resistant P. aeruginosa isolates in Taiwan and in
Korea, respectively [71,72]. In France, single novel
derivatives of OXA-13 (OXA-19 and OXA-28) and
OXA-18 were found in a few P. aeruginosa iso-
lates, and OXA-45 was found in one P. aeruginosa
isolate from Texas, USA [5,69,70].
CONCLUSION
Numerous chromosomally encoded ESBLs have
been described worldwide, and it is likely that
many more will be discovered in the future. These
enzymes may represent potential threats, since
gene-capture units may mobilise them onto
plasmids and may enhance their dissemination.
Several of these genes have already been mobi-
lised, with CTX-M types being very successful.
Others, SFO-1, BES-1, BEL-1, TLA-1 and TLA-2,
are as yet very rare and are geographically
localised, whereas yet others, GES, PER and
VEB, have been described on several continents.
In many cases, extensive epidemiological surveys
have not yet been undertaken, and the precise
distribution is not known. Identiﬁcation and
knowledge of distribution may more likely reﬂect
the interest of research teams than true preva-
lence. With ESBLs, the saying ‘we ﬁnd only what
we are looking for’ is very appropriate.
Another worrying aspect is that some of these
enzymes may extend their spectrum of hydrolysis
towards carbapenems by simple point mutations,
as illustrated by GES-2. Furthermore, the number
of point-mutant derivatives of GES variants and
their geographical spread signals a worrying
ongoing evolution in this family of enzymes.
Unlike the genes of the TEM-, SHV- and CTX-
M-type enzymes, those of most minor ESBLs are
carried by integrons in association with other
resistance genes (mainly aminoglycoside resis-
tance genes), thus ensuring co-resistance, co-
expression and co-selection of a multiresistance
phenotype. Furthermore, as shown for the blaVEB-1
gene, a frequent association with plasmid-en-
coded rifampicin and quinolone resistance genes
may be observed [43,51].
Minor ESBLs, although currently very rare and
geographically localised, may rapidly become
major concerns, especially since regional occur-
rence may rapidly be ampliﬁed through trans-
continental transfer of resistance genes, as now
exempliﬁed repeatedly [29,48]. This scenario
highlights the difﬁcult problem of screening
patients for carriage of multidrug-resistant iso-
lates upon hospital entry.
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